In fact, adoptive transfer of rIL-33-activated TI PD-1+ ILC2 into ILC2-deficient mice controls tumor progression, indicating that rIL-33-activated TI PD-1+ ILC2 is functional and enhances antitumor immunity (Moral et al., 2020). Here, PDCD1 is linked to neoplasm.